Our current findings provide one of the first reports demonstrating that sunitinib can be used as a precision agent to potentiate the anti-cancer effects of rhTRAIL in colon carcinoma through a JNK-mediated mechanism that is specifically linked to XIAP antagonism. The gene discussed is XIAP; the disease is colon carcinoma.